Top Hires Quarterly: VC, Early Stage and High Growth
Q3 2019 EMEA
This quarter’s successful placements include:
- Chief Financial Officer, genetic testing, France
- Chief Business Officer, oncology, UK
- Chief Scientific Officer, immunology, UK
- Head of European Sales, A.I. image-based diagnostics, Finland
- Head of Operations, precision medicine, Switzerland
- Chairperson, immunology, UK
- Country Manager, animal health, Netherlands
- General Manager, animal health, Norway
- Principal, Life Science VC, Netherlands
Newly opened projects include:
- Head of Commercial, digital health
- CBO, oncology
- Non-Executive Chair, ophthalmology
- Principal, European VC
- CMO, rare diseases
|
- Head of Discovery, A.I. discovery
- VP Europe, medical devices
- CEO, immunology
- VP Research, regenerative medicine
- CBO, small molecule
|
Areas of focus this quarter include but are not limited to:
- Artificial intelligence
- CNS
- Animal Health
|
- Immunology
- Gene Therapy
- Diagnostics
|
- Precision Medicine
- Vaccines
- Antimicrobials
|
- New office opens in Brussels and six key appointments are made worldwide
- Medtech specialist, Penny Sadler heads the Belgium office, with 26 years’ global search experience
- The Paris, Frankfurt and New Jersey offices and the R&D team in London are all strengthened with senior hires
- Global market leader and largest global executive search firm dedicated to the Life Sciences and committed to delivering outstanding leadership
- 90+ sector experts from a diversity of backgrounds working across 14 global offices across US, Europe and APAC
- Unrivalled network with the Life Sciences community with c. 260+ assignments each year across all segments of the industry.
- Deep understanding of talent needs, business models, sector trends, scientific evolution, innovation and competitive positioning
- Large proportion of search work for VC, PE and angel-funded biotech, medtech, and digital health companies
- Working with 50+ VC and PE funds across US, UK and EMEA
- 400+ senior leadership assignments for investor portfolio companies
|
 |
